Indeed, the inhibition of EGFR in cancer patients leads to skin toxicity, whose severity has shown to be positively correlated with patients’ survival and hence could be a surrogate marker of tumor response to EGFRIs [7]. The gene discussed is EGFR; the disease is neoplasm.